Headless WordPress - PROD

Mechanistic insights reveal opportunities for addressing the fundamental pathophysiology of type 1 diabetes

https://www.sharecare.com/hcp/endocrinology-diabetes-metabolism/evolution-beta-cell-replacement-clinical-reality

The evolution of β-cell replacement: From concept to clinical reality

Precision targeting of autoimmune mechanisms creates opportunities for disease modification during preclinical phases

https://www.sharecare.com/hcp/endocrinology-diabetes-metabolism/immunomodulation-type1-diabetes

Immunomodulation in early-stage Type 1 diabetes: Redefining intervention windows

Implementing autoantibody screening protocols and addressing social determinants in the era of disease-modifying therapies

https://www.sharecare.com/hcp/endocrinology-diabetes-metabolism/type1-diabetes-screening-equity

Screening guidelines and access equity in early-stage Type 1 diabetes

Advancing disease modification requires alignment of biologic innovation with structural and social determinants of health

https://www.sharecare.com/hcp/endocrinology-diabetes-metabolism/type1-diabetes-therapeutic-barriers

Integrating emerging therapeutic strategies with real-world barriers in Type 1 diabetes care

Featured Content

Endocrinologist and Summon Health CEO Sandra Sobel, MD shares expert insights on early T1D detection and emerging therapies.